KPV

Order KPV 10mg from Eternal Peptides, a trusted peptides provider with rigorous third-party testing by leading labs to ensure exceptional purity and reliable research outcomes. KPV is a tripeptide fragment derived from alpha-melanocyte stimulating hormone (α-MSH), designed for research in inflammatory response, gut barrier function, and immunomodulation studies. Get KPV 10mg vials at competitive pricing, with free USPS shipping for orders over $200 and dedicated support. KPV is sold for research use only.

What is KPV?

KPV is a naturally occurring tripeptide consisting of the amino acid sequence Lysine-Proline-Valine (Lys-Pro-Val). It represents the C-terminal fragment of alpha-melanocyte stimulating hormone (α-MSH), a tridecapeptide hormone involved in various physiological processes including pigmentation, inflammation, and immune regulation.

KPV was identified as a biologically active fragment of α-MSH during research investigating the hormone’s anti-inflammatory properties in the 1980s and 1990s, when scientists discovered that this short sequence retained significant immunomodulatory activity without the pigmentation effects associated with the full-length hormone.

The scientific literature primarily investigates KPV for its potent anti-inflammatory and immunomodulatory properties, with research focusing on inflammatory bowel disease models, wound healing, antimicrobial activity, and epithelial barrier function. Studies examine its effects on cytokine production, NF-κB pathway inhibition, and mast cell stabilization across various inflammatory conditions.

Most published findings on KPV derive from in vitro cellular assays and animal models, particularly rodent studies of colitis and dermatitis, though some preliminary human data exists in dermatological applications.

For research use, KPV demonstrates excellent aqueous solubility and stability in physiological conditions, resisting rapid enzymatic degradation better than many longer peptide sequences.

How KPV Works: Mechanistic Overview

KPV exerts its effects primarily through potent anti-inflammatory pathway modulation, particularly inhibition of nuclear factor kappa B (NF-κB) signaling, reduction of pro-inflammatory cytokine production, and stabilization of mast cell degranulation[1].

The tripeptide enters cells through endocytosis and peptide transport mechanisms, where it directly interferes with inflammatory transcription factor activation without requiring melanocortin receptor binding, distinguishing it from its parent hormone α-MSH. 

Research demonstrates that KPV reduces production of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), and other inflammatory mediators in stimulated immune cells[2].

Also, animal studies of inflammatory bowel disease show reduced colonic inflammation, improved histological scores, and decreased disease activity indices following KPV administration[3]. Cellular assays reveal that KPV protects epithelial barrier integrity, reduces oxidative stress markers, and demonstrates antimicrobial properties against various pathogens, with wound healing models showing accelerated closure rates and improved tissue remodeling.

NF-κB Pathway Inhibition

KPV’s primary anti-inflammatory mechanism involves direct inhibition of the nuclear factor kappa B (NF-κB) signaling pathway, a master regulator of inflammatory gene expression[1]. The tripeptide enters cells and interferes with the translocation of NF-κB from the cytoplasm to the nucleus, preventing the transcription of pro-inflammatory genes.

In vitro studies using lipopolysaccharide (LPS)-stimulated immune cells demonstrate that KPV treatment significantly reduces NF-κB activation, as measured by electrophoretic mobility shift assays and reporter gene assays[4]. 

This inhibition occurs in a dose-dependent manner and does not appear to involve melanocortin receptor activation, suggesting a novel mechanism distinct from α-MSH. Animal models of colitis show that KPV administration reduces nuclear NF-κB levels in intestinal tissue, correlating with decreased expression of downstream inflammatory mediators including COX-2, iNOS, and adhesion molecules[2]. 

The peptide’s ability to suppress NF-κB activation contributes to observed reductions in tissue inflammation, immune cell infiltration, and organ damage across multiple experimental inflammatory disease models.

Cytokine Production Modulation

KPV significantly reduces the production of pro-inflammatory cytokines from activated immune cells, including macrophages, dendritic cells, and T lymphocytes.

Cellular studies demonstrate that KPV treatment decreases TNF-α, IL-6, IL-8, IL-1β, and interferon-gamma (IFN-γ) secretion from cells stimulated with bacterial components, allergens, or other inflammatory triggers[1]. This cytokine reduction occurs at both transcriptional and post-transcriptional levels, with research showing decreased mRNA expression and reduced protein secretion.

Conversely, KPV appears to preserve or slightly enhance anti-inflammatory cytokine production, including IL-10, suggesting a rebalancing effect on immune responses rather than broad immunosuppression. In experimental colitis models, KPV-treated animals exhibit markedly reduced intestinal tissue levels of pro-inflammatory cytokines alongside improved histological scores and reduced clinical disease severity[2]. 

The cytokine-modulating effects extend to mast cells, where KPV prevents degranulation and histamine release in response to allergic triggers, as demonstrated in both isolated mast cell preparations and animal models of allergic inflammation.

Epithelial Barrier Protection

Research demonstrates that KPV protects epithelial barrier integrity in intestinal, dermal, and respiratory tissues subjected to inflammatory challenges[2]. 

In cell culture models using intestinal epithelial monolayers, KPV treatment preserves tight junction protein expression and distribution, maintaining transepithelial electrical resistance (TEER) when cells are exposed to inflammatory cytokines or bacterial products. The peptide upregulates expression of tight junction proteins including occludin, claudins, and zonula occludens-1 (ZO-1), while preventing their degradation and redistribution under stress conditions.

Animal studies of inflammatory bowel disease show that KPV administration reduces intestinal permeability, as measured by reduced translocation of orally administered tracers into systemic circulation. This barrier-protective effect correlates with decreased bacterial translocation, reduced systemic endotoxin levels, and improved survival in severe colitis models.

Dermal wound healing studies reveal that KPV accelerates re-epithelialization, promotes organized collagen deposition, and enhances barrier restoration compared to control treatments, suggesting broad epithelial protective mechanisms across tissue types[5].

What this means is that KPV helps maintain the protective barrier of gut and skin tissues, keeping cells tightly connected and preventing harmful substances from crossing through damaged barriers in laboratory studies.

Antimicrobial Activity

KPV demonstrates direct antimicrobial properties against various bacterial and fungal pathogens in microbiological assays, contributing to its protective effects in infection and inflammation models.

In vitro antimicrobial testing reveals that KPV inhibits growth of Staphylococcus aureus, Candida albicans, and certain gram-negative bacteria at physiologically relevant concentrations. The peptide appears to disrupt microbial membrane integrity and interfere with biofilm formation, mechanisms distinct from conventional antibiotics[6].

Research using infected wound models shows that topical KPV application reduces bacterial burden, accelerates healing, and decreases local inflammation compared to untreated controls. 

In inflammatory bowel disease models where intestinal barrier compromise allows bacterial translocation, KPV treatment reduces bacterial presence in mesenteric lymph nodes and systemic organs, suggesting both direct antimicrobial effects and indirect benefits through barrier protection[7].

The antimicrobial activity occurs without apparent development of resistance in repeated exposure studies, though long-term resistance potential requires further investigation. This dual anti-inflammatory and antimicrobial profile makes KPV particularly interesting for research into conditions where inflammation and microbial dysbiosis interact.

Evidence Limitations

While KPV demonstrates consistent anti-inflammatory and barrier-protective effects across multiple in vitro and animal model systems, controlled human clinical evidence remains extremely limited.

The majority of mechanistic insights and efficacy data derive from cellular assays and rodent studies, primarily using colitis, dermatitis, and wound healing models. Some preliminary human data exists for topical dermatological applications, but rigorous randomized controlled trials evaluating systemic KPV administration in human inflammatory conditions are absent from peer-reviewed literature.

The bioavailability, pharmacokinetics, optimal dosing, and safety profile of KPV in humans have not been systematically established through clinical research meeting current regulatory standards.

As such, researchers should interpret all findings within appropriate preclinical contexts and recognize that observed anti-inflammatory effects in controlled laboratory models do not automatically translate to human therapeutic efficacy or establish clinical safety profiles for any human applications.

KPV Research Value (Applications)

KPV has generated significant research interest across inflammatory disease modeling, particularly in studies examining inflammatory bowel disease, dermatological inflammation, wound healing, allergic responses, and mucosal barrier function.

Since these applications emerge from observations in cellular assays, tissue culture systems, and rodent models investigating anti-inflammatory mechanisms and epithelial protection, they do not imply any established human therapeutic benefits or veterinary applications.

KPV is not approved by regulatory agencies such as the FDA for medical use, and Eternal Peptides does not promote, advocate for, or support any human consumption or clinical applications of this compound.

Inflammatory Bowel Disease Models

Animal studies using chemically induced colitis models demonstrate that KPV administration significantly reduces disease severity, as measured by clinical scoring systems, weight loss prevention, colon length preservation, and histological damage assessment[8].

Research employing dextran sodium sulfate (DSS) and trinitrobenzene sulfonic acid (TNBS) colitis protocols shows that KPV-treated rodents exhibit decreased inflammatory cell infiltration, reduced crypt damage, and lower ulceration scores compared to control groups[9]. 

The peptide reduces colonic tissue levels of pro-inflammatory cytokines including TNF-α, IL-6, IL-1β, and chemokines that recruit immune cells to inflamed tissue. Molecular studies reveal decreased NF-κB activation in intestinal epithelial cells and reduced myeloperoxidase activity, a marker of neutrophil infiltration.

In short, lab animals with experimentally induced intestinal inflammation show less severe disease, reduced tissue damage, and better-preserved gut barrier function when treated with KPV compared to untreated animals.

Dermatological Inflammation Research

Dermatitis models in rodents demonstrate that topical or systemic KPV application reduces skin inflammation, epidermal thickening, immune cell infiltration, and clinical severity scores across various protocols, including contact hypersensitivity and atopic dermatitis-like conditions[10]. 

Research using hapten-induced contact dermatitis shows that KPV treatment decreases ear or skin swelling, reduces erythema, and lowers histological inflammation scores[4]. The peptide reduces local production of inflammatory mediators and decreases mast cell degranulation in affected skin tissues.

Similarly, in vitro studies using keratinocyte cultures reveal that KPV protects against inflammatory cytokine-induced damage, preserves cellular viability, and reduces oxidative stress markers. Psoriasis-like inflammation models demonstrate that KPV reduces epidermal hyperplasia, decreases parakeratosis, and normalizes keratinocyte differentiation markers in treated animals compared to vehicle controls.

In summary, these studies show that KPV treatment reduces swelling, redness, and tissue damage while protecting skin cells from inflammatory stress in culture dish experiments.

Wound Healing and Tissue Repair

Experimental wound models reveal that KPV application accelerates healing kinetics, improves wound closure rates, and enhances tissue remodeling quality across dermal, oral mucosal, and intestinal wound paradigms. Research using full-thickness excisional wounds in rodents shows that KPV-treated wounds exhibit faster re-epithelialization, increased granulation tissue formation, and more organized collagen deposition during the remodeling phase.

The peptide reduces inflammatory cell persistence in wound beds while promoting appropriate angiogenesis and fibroblast activity. Diabetic wound models, which exhibit impaired healing, demonstrate particular responsiveness to KPV with significant improvements in healing rates and reduced chronic inflammation[11]. Intestinal anastomosis models show that perioperative KPV administration improves surgical wound healing, reduces anastomotic leakage rates, and decreases perianastomotic inflammation in experimental settings.

This means that, in lab animals, skin or internal wounds heal faster and with better-quality tissue formation when treated with KPV, including in diabetes models where healing is normally impaired.

Allergic Response Modulation

Mast cell research demonstrates that KPV prevents degranulation and histamine release when cells are exposed to allergic triggers, both in isolated mast cell preparations and in animal models of allergic inflammation.

Studies using IgE-mediated mast cell activation protocols show that KPV pretreatment significantly reduces mediator release including histamine, leukotrienes, and pro-inflammatory cytokines[1]. 

Animal models of allergic airway inflammation reveal that KPV administration reduces bronchoalveolar lavage fluid cellularity, decreases airway hyperresponsiveness, and lowers lung tissue eosinophil infiltration following allergen challenge. The peptide modulates Th2-type immune responses, reducing IL-4, IL-5, and IL-13 production while maintaining balanced immune function.

KPV treatment may also help reduce anaphylactic responses in food allergy models, decreasing systemic histamine levels and improving survival rates in severe allergic reaction protocols.

Simply, KPV prevents allergic immune cells from releasing inflammation-causing chemicals, thus reducing allergic reactions in animal models of asthma and severe allergies.

Peptide Characteristics

Note: KPV represents the C-terminal tripeptide sequence of alpha-melanocyte stimulating hormone (α-MSH) and retains potent anti-inflammatory activity without the melanocortin receptor-mediated effects associated with the full-length hormone.

KPV: Handling & Storage Guidelines

Proper handling and storage of KPV is essential to maintain peptide integrity, biological activity, and experimental reproducibility throughout research protocols.

• Lyophilized Powder: Store unopened vials at -20°C (-4°F) in a freezer, protected from light and moisture. Under these conditions, lyophilized KPV remains stable for 24-36 months. Transfer vials to frozen storage upon receipt.
• Reconstitution: Reconstitute KPV using sterile water, bacteriostatic water, or phosphate-buffered saline (PBS) to achieve desired concentrations, typically 1-5 mg/mL for optimal stability and handling.
  • Allow the lyophilized powder to reach room temperature before adding reconstitution solution, then gently swirl to dissolve completely. Avoid creating air bubbles or foam during reconstitution.
• Aliquots: Reconstituted KPV should be stored at 2-8°C (36-46°F) for short-term use up to 14 days. For extended storage beyond two weeks, aliquot the solution into single-use portions in sterile cryovials and store at -20°C (-4°F) or -80°C (-112°F). This aliquoting strategy prevents repeated freeze-thaw cycles that can degrade peptide integrity.
• Freeze-Thaw Cycles: Minimize freeze-thaw cycles to no more than 2-3 occurrences. Each cycle increases the risk of peptide aggregation, structural degradation, and reduced biological activity. Thaw frozen aliquots slowly at 2-8°C rather than at room temperature or using accelerated methods.
• Laboratory Safety and Compliance: Handle KPV using appropriate personal protective equipment, including gloves, lab coat, and eye protection. Work within institutional biosafety and chemical handling guidelines. 
• Waste Disposal: Dispose of unused peptide solutions and materials according to institutional waste management protocols. Maintain proper documentation of peptide handling, storage conditions, and expiration tracking as part of good laboratory practices.

Note: For optimal experimental outcomes and confidence in research material quality, order bacteriostatic water (sterile water) from Eternal Peptides with your KPV.

COA / Quality Assurance

Eternal Peptides provides comprehensive Certificates of Analysis (COAs) for every KPV lot for transparency and traceability. Each COA delivers detailed analytical data essential for experimental reproducibility, regulatory compliance, and quality assurance documentation.

COA Contents:

• Peptide Identity Verification: Confirmed through high-performance liquid chromatography (HPLC) retention time matching and mass spectrometry analysis, verifying the correct molecular weight of 342.43 g/mol and tripeptide sequence (Lys-Pro-Val).
• Purity Assessment: Quantified via HPLC with UV detection, measuring the percentage of target peptide versus impurities, synthesis byproducts, or degradation products, typically demonstrating ≥98% purity for research-grade KPV.
• Sterility Testing: Conducted according to USP <71> sterility testing protocols to ensure freedom from bacterial and fungal contamination in lyophilized products.
• Endotoxin Levels: Measured via Limulus Amebocyte Lysate (LAL) assay to ensure compliance with research-grade standards, typically <1.0 EU/mg, critical for inflammatory research where endotoxin contamination could confound experimental results.
• Storage Recommendations: Tailored guidance for optimal stability based on the specific tested lot, including temperature requirements and recommended reconstitution procedures.

Eternal Peptides partners with leading independent analytical laboratories, including Janoshik and Finnrick Analytics, to conduct rigorous independent testing. This means reliable results that meet international analytical standards and support publication-quality research.

Additionally, all COAs are lot-specific, uniquely identified by batch numbers printed on product vials, and readily accessible through the Lab Tests page on our website.

Legal / Regulatory Disclaimer

KPV is strictly for laboratory research purposes only and is not approved by the FDA or any regulatory authority for human consumption, veterinary use, clinical administration, therapeutic applications, or diagnostic procedures.

The safety and efficacy of KPV in humans have not been established through controlled clinical trials meeting regulatory standards. This product is intended exclusively for qualified researchers operating within institutional review board (IRB) approved protocols and appropriate biosafety frameworks.

Purchasers are solely responsible for ensuring compliance with all applicable federal, state, and local regulations governing research peptides, as well as institutional policies. Eternal Peptides does not condone, support, or provide guidance for any non-research applications of this compound.

Scientific References

1. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. Epub 2012 Jun 23.

https://pmc.ncbi.nlm.nih.gov/articles/PMC3403564/ 

2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008 Jan;134(1):166-78. doi: 10.1053/j.gastro.2007.10.026. Epub 2007 Oct 17.

https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/ 

3. Marotti V, Xu Y, Bohns Michalowski C, Zhang W, Domingues I, Ameraoui H, Moreels TG, Baatsen P, Van Hul M, Muccioli GG, Cani PD, Alhouayek M, Malfanti A, Beloqui A. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Bioact Mater. 2023 Oct 11;32:206-221.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10582360/ 

4. Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii52-5.

https://pmc.ncbi.nlm.nih.gov/articles/PMC2095288/ 

5. Adnan SB, Maarof M, Fauzi MB, Fadilah NIM. Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review. Int J Med Sci 2025; 22(16):4175-4200. 

https://www.medsci.org/v22p4175.htm 

6. Mercer DK, O’Neil DA. Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response. Front Immunol. 2020 Sep 17;11:2177.

https://pmc.ncbi.nlm.nih.gov/articles/PMC7533533/ 

7. Zhang D, Jiang L, Yu F, Yan P, Liu Y, Wu Y, Yang X. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS. Front Pharmacol. 2024 Aug 15;15:1442876.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11357942/ 

8. Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M, Han MK, Garg P, Xiao B, Merlin D. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016 May;2(3):340-357.

https://pmc.ncbi.nlm.nih.gov/articles/PMC4957955/ 

9. Yang C, Merlin D. Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-induced Model. Inflamm Bowel Dis. 2024 May 2;30(5):844-853.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11063560/ 

10. Kasturi Pawar, Chandra S. Kolli, Vijaya K. Rangari, R. Jayachandra Babu, Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin, Journal of Pharmaceutical Sciences, Volume 106, Issue 7, 2017, Pages 1814-1820, ISSN 0022-3549.

https://www.sciencedirect.com/science/article/abs/pii/S0022354917301740 

11. Pradhan L, Nabzdyk C, Andersen ND, LoGerfo FW, Veves A. Inflammation and neuropeptides: the connection in diabetic wound healing. Expert Rev Mol Med. 2009 Jan 13;11:e2.

https://pmc.ncbi.nlm.nih.gov/articles/PMC3708299/